Dan Denney is the Founder and the Chief Executive Officer (CEO) of Ataraxis Biosciences, Inc.
Denney is a mission-driven scientist and sees the role of scientists and science as working for the greater good. Always one to prefer “tough problems,” he has been at the forefront of both basic and clinical cancer research for much of his career. Denney worked at Sloan Kettering in NYC and holds two patents for his work related to the cancer drug Interferon.
Denney earned a PhD in microbiology and immunology from Stanford Medical School. He also did his post-doctoral work in chemistry at Stanford, where he was awarded a prestigious Merck Fellowship. The award is presented annually to only a handful of recipients worldwide.
After leaving Stanford, Denney founded Genitope Corporation, a biotechnology company focused on the research and development of novel immunotherapies for cancer patients battling non-Hodgkin’s lymphoma and CLL. Denney led the company for 12 years. He raised several rounds of private capital before taking Genitope public in 2003.
More recently Denney has turned his attention to the nation’s food supply in an effort to bring scientific testing – rather than just the honor system – to verify drug-free label claims. Denney strongly believes people have a right to know what is in the food they are buying and eating. He founded Ataraxis Biosciences in order to give forward-thinking companies and people a quick, simple, and inexpensive way to test meat for man-made drugs.